The correlation between human epidermal growth factor receptor 2 expression and gastric carcinoma histology

doi:10.3969/j.issn.1009-976X.2021.04.007

Abstract

Abstract: Objective To analysis the positive rate of human epidermal growth factor receptor 2 （HER2） expression among different endoscopic biopsy sites of gastric cancer and its correlation withgastric cancer histological characteristics. Methods Totally 108 cases（87 cases were gastric cancer group and 21 cases were chronic superficial gastritis patientsas normal gastric mucosa group） of inpatients who underwent therapy in The Second Affiliated Hospital of Xinjiang Medical University from January 2017 to January 2020 were collected retrospectively. After admission, the specimens obtained by endoscopy or surgery were pathologically examined. The HER2 positive rates among different biopsy sites in endoscopy and expression of human epidermal growth factor receptor 2 and clinicopathologic features were compared. Results Compared with the normal gastric mucosa group, the gastric cancer group had higherpositive rate of HER2 （17.2% vs. 0.0%,P<0.05）. HER2 positive rates from biopsy specimen were 100%, 90%, 44% and 100% in the surperfical spreading portion, ulcer mound, ulcer bed, and mass portion, respectively. The pathological type of tubular adenocarcinoma and the microscopically free signet ring cells had higher positive rate of HER2 than other tissue types of carcinomas and the microscopically visible signet ring cells（23.0%, 23.6% vs. 3.8%, 6.3%, respectively,P<0.05）. Conclusion The expression of human epidermal growth factor receptor 2 in gastric cancer is correlated with the histopathological characteristics, the positive rate of HER2 in gastric cancer with microscopically free signet ring cells may be higher,when evaluating the expression of HER2 in endoscopy biopsy specimens, the surperfical spreading portion and mass portion should be selected, which can provide reference for comprehensive targeted therapy of gastric cancer.

Key words: gastric carcinoma, histology, human epidermal growth factor receptor 2, endoscopic biopsy

摘要： 目的分析内镜下不同活检部位胃癌组织中人类表皮生长因子受体2（HER2）表达阳性率及与胃癌组织学特点相关性。方法收集本院2017年1月至2020年1月收治的胃癌患者87例列入胃癌组,选取同期住院治疗的慢性浅表型胃炎患者21例列入正常胃黏膜组,入院后将内镜或手术获得的标本行病理检查,比较内镜标本中不同活检部位组织的HER2阳性率和胃癌病理学特征与人类表皮生长因子受体2表达水平的关系。结果胃癌组HER2阳性率较胃黏膜正常组更高（17.2%和0.0%,P<0.05）,内镜下肿瘤浅表弥漫部、溃疡隆起部、溃疡床及肿块突起部组织HER2阳性率分别是100%、90%、44%、100%,病理类型为管状腺癌及镜下不含印戒细胞较其他组织类型癌和镜下含印戒细胞HER2阳性率高（分别是23.0%、23.6%和3.8%、6.3%,P<0.05）。结论胃癌HER2表达水平与其病理组织学特点具有相关性,镜下不含印戒细胞的胃癌组织HER2阳性率可能更高,在评估内镜活检标本HER2表达时应着重选择肿瘤浅表弥漫部和肿块突起部,可以为胃癌靶向治疗提供参考。

关键词: 胃癌, 组织学, 人类表皮生长因子受体2, 内镜活检

CLC Number:

R735.2

LIU Jiang, PAHEREDINI·Yusufu, LI Jian-gang, MA Bo, LI Liang, WANG Jun, WANG Tong, Ahetibieke. The correlation between human epidermal growth factor receptor 2 expression and gastric carcinoma histology[J]. Lingnan Modern Clinics In Surgery, 2021, 21(04): 411-414.

刘江, 帕合热迪尼·玉素甫, 李建刚, 马博, 李亮, 王俊, 王彤, 阿合提别克. 人类表皮生长因子受体2表达与胃癌组织学的相关性研究[J]. 岭南现代临床外科, 2021, 21(04): 411-414.

References

[1] 国家卫生健康委员会. 胃癌诊疗规范(2018年版)[J]. 肿瘤综合治疗电子杂志,2019,5(1):55-82.
[2] Nie S, Yang G, Lu H.Current Molecular Targeted Agents for Advanced Gastric Cancer[J]. Onco Targets Ther, 2020,13:4075-4088.
[3] Ajani JA, D′Amico TA, Almhanna K, et al. Gastric Cancer,Version 3.2016,NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2016, 14(10): 1286-1312.
[4] Luo W, Fedda F,Lynch P, et al.CDH1 Gene and Hereditary Diffuse Gastric Cancer Syndrome: Molecular and Histological Alterations and Implications for Diagnosis And Treatment[J]. Front Pharmacol, 2018,9:1421.
[5] Yamamoto A, Kawaguchi Y, Shiraishi K, et al.The impact of histological type on the accuracy of preoperative N staging in patients with gastric cancer[J]. World J Surg Oncol,2019,17(1):130.
[6] Charalampakis N, Nogueras González GM, Elimova E,et al.The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation[J]. Oncology,2016,90(5):239-247.
[7] 《免疫组织化学检测技术共识》编写组. 免疫组织化学检测技术共识[J]. 中华病理学杂志,2019,48(2):87-91.
[8] 《胃癌HER2检测指南2016版》专家组. 《胃癌HER2检测指南》(2016版)[J]. 中华病理学杂志,2016,45(8):528-532.
[9] Cruz-Reyes C, Gamboa-Dominguez A.HER2 amplification in gastric cancer is a rare event restricted to the intestinal phenotype[J]. Int J Surg Pathol,2013, 21(3):240-246.
[10] Shan L, Ying J, Lu N.HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population[J]. Diagn Pathol,2013,8:76.
[11] Kunz PL, Mojtahed A, Fisher GA, et al.HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment[J]. Appl Immunohistochem Mol Morphol, 2012,20(1):13-24.
[12] 李玉林. 病理学[M]. 8版. 北京:人民卫生出版社,2013:210-211.
[13] Janjigian YY, Werner D, Pauligk C, et al.Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis[J]. Ann Oncol, 2012,23(10):2656-2662.
[14] Yoshida H, Yamamoto N, Taniguchi H, et al.Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma[J]. Virchows Arch, 2014,465(2):145-154.
[15] Tominaga N, Gotoda T, Hara M, et al.Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer[J]. Gastric Cancer, 2016,19(2):553-560.
[16] Tanner M, Hollmén M, Junttila TT, et al.Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab[J]. Ann Oncol,2005,16(2):273-278.
[17] Lee S, de Boer WB, Fermoyle S, et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections[J]. Histopathology, 2011,59(5):832-840.
[18] Subasinghe D, Acott N, Kumarasinghe MP.A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma[J].Gastrointest Endosc, 2019,90(1):44-54.
[19] Bartley AN, Washington MK, Colasacco C, et al.HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology[J]. J Clin Oncol, 2017,35(4):446-464.
[20] Machado-Neves R, Vale J, Eloy C, et al.HER2 genomic heterogeneity is a frequent event in gastroesophageal adenocarcinoma and correlates with tumor morphology[J]. Pathol Res Pract, 2020,216(9):153090.
[21] Arai T.Where does signet-ring cell carcinoma come from and where does it go?[J]. Gastric Cancer, 2019,22(4):651-652.